Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

bullseyecatnip 9 posts  |  Last Activity: 6 hours ago Member since: Jun 24, 2015
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Shorts, Take Micron to Zero

    by jekdc Feb 11, 2016 10:09 AM
    bullseyecatnip bullseyecatnip 6 hours ago Flag

    It appears you would benefit from a mental health check and anger management. We should say a quick pray for you and then put you on ignore, where I thought I had you before.

  • Reply to

    Obama's chickens have ome home to roost

    by bamapride57 Feb 8, 2016 11:22 AM
    bullseyecatnip bullseyecatnip Feb 9, 2016 5:57 PM Flag

    Obama is loving this... watching US energy companies being taken to the woodshed and beaten to death and his $10 tax on top is the nail on the coffin. 100,000s of people in energy related business with lose jobs, homes and many families will be new er recover... there isn't enough time.

  • Reply to

    Just when I was looking at buying in

    by navrbody Feb 8, 2016 5:26 PM
    bullseyecatnip bullseyecatnip Feb 9, 2016 7:56 AM Flag

    And as for china... they don't need a war with us.... only to keep buying us up and eventually "reposting" a good chuck of the U.S.

  • Reply to

    Just when I was looking at buying in

    by navrbody Feb 8, 2016 5:26 PM
    bullseyecatnip bullseyecatnip Feb 9, 2016 7:55 AM Flag

    MU is one of the safest tech to own with excellent upside if you plan to hold 3-5 years. They could rise 2-3X and perhaps 4 X higher by then. They are a much better and more diversified MU than they were last time their PPS was $5-10 (when everyone said stay away). When it was $5-10 I bought more oMU than anything else and it served me VERY well. I didn't sell all in the 30s, but I sold plenty. Admit to buying back in too early 17s and adding 10/11s, but I plan to add more later this year. Oh, and can't wait until Obama is out of office. If Dems are elected you can flush this country down the toilet. The biggest terrorist threat is not ISIS its this POTUS... who pills on massive debt and has killed US coal and oil, as if he's a middle-east trojan horse working us from within.

  • bullseyecatnip by bullseyecatnip Nov 5, 2015 12:49 PM Flag

    Thanks everyone, who's posts were presented with integrity over the years. To some of you, I'm sure I owe you an apology or two over the years for reading your posts too quickly or too much into them and then judging you/them harshly. Perhaps it was a time when I way off base or had a bad day that crept into my posts. In any event, to all those folks, I apologize.

    There are many excellent posters here who provide objective, factual, info and thought provoking opinions. I appreciate them alt.

    I don't have much of anything of value to contribute. So, from time to time, I'll just read from afar, as I wait with fellow longs for official company news what I believe will bring us all excellent returns someday. IMO, our decisions to buy and patience to hold, no matter what the PPS will be rewarded.

    Best wishes and happy holiday season to everyone here, the KERX team, and the families they help!

  • Reply to

    Mixed signals...

    by daoryebba60 Oct 21, 2015 10:41 AM
    bullseyecatnip bullseyecatnip Oct 21, 2015 10:47 AM Flag

    Relax... seas might remain choppy for a while, but the KERX boat has a new captain and first mate on the board that will eventually lift any anchors holding us back and move us swiftly to calmer waters and paradise. Put these shares in a sock draw, set your alerts for official company news and quarterly updates... relax and enjoy the holidays....

  • bullseyecatnip by bullseyecatnip Aug 8, 2015 7:05 AM Flag

    For many months prior to approval, the FORMER CEO repeatedly stressed that a small focused sales team could "easily" penetrate those proving care services where this drug would be a fit. I understand needing insurance coverage, samples, and all the other reasons why this could take time to gain traction.... but I can't help but wonder if part of the problem is as simple as the majority of the salesforce is inexperienced and ineffective. They didn't work smart enough to fill their funnels with qualified prospects to prime the pump. Now it will be a slower crawl rather than a pop.

    I remain long, although never though we'd be 6-7s after such successful research, trial results and all the benefits to patients, providers and insurers. So this makes we wonder (conspiracy) if their competition is somehow delaying their acceptance but spreading FUD with prescribers or paying some in some ways. such as paid speaking engagements, trips, etc

    Perhaps these are some of the reason they are hiring more sales reps. Hoping to be back in the teens with in 5-7 months and a partnership in Europe and more success in Japan. And please, no BO until the PPS is at least within 10% of previous high and ideally breaking 20 before a BO is accepted.

  • bullseyecatnip bullseyecatnip Aug 4, 2015 10:44 AM Flag

    And if could go to 2-3 dollars like before and unto $40.... that's when fortunes are made. BTW, I am long SLW and plan to hold forever.

  • BOSTON, June 24, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that two national insurance providers have added AuryxiaTM to their Medicare Part D formularies. Auryxia is the first and only absorbable, iron-based phosphate binder for the treatment of elevated serum phosphorus levels in people with chronic kidney disease on dialysis. Together, these new formularies will increase unrestricted access to Auryxia, across Medicare Part D and commercial insurance providers, to approximately 65 percent of people in the U.S. currently taking phosphate binders.

    "The inclusion of Auryxia on these major insurance providers' Part D formularies, which we expect will start processing claims in the third quarter, significantly expands unrestricted access to Auryxia for people on dialysis and their caregivers," said Greg Madison, Chief Executive Officer of Keryx Biopharmaceuticals. "We are progressing nicely towards our goal of broad, unrestricted access to approximately 80 percent of phosphate binder prescriptions, across both Medicare Part D and commercial insurance providers, within 12 months post-approval. Looking ahead, we are focused on continuing to raise awareness of Auryxia's clinical profile among the prescribing community and ensuring that the vast majority of dialysis patients have access to this important medicine."

    Auryxia is currently approved to treat elevated serum phosphorus levels in the estimated 450,000 people in the U.S. who have End Stage Renal Disease (ESRD) and require dialysis treatment. The majority of ESRD patients require chronic treatment with phosphate-binding medicines to lower and maintain serum phosphorus at acceptable levels. Medicare Part D and commercial insurance providers cover most of the healthcare costs for people with ESRD and account for approximately 90 percent of all prescriptions for p

OGXI
0.62+0.06(+10.71%)2:08 PMEST